Literature DB >> 33489629

Efficacy of 5-Fluorouracil in the Treatment of Pterygium.

Sobia U Shah1, Tanveer Ahmed1,2, Anum Badar3, Maeirah Shafique4, Sidra Malik5, Bushra Aaqil6.   

Abstract

Objective To determine the efficacy of 5-Fluorouracil (FU) in the treatment of pterygium. Methodology After meeting the inclusion criteria 101 patients were enrolled in this study. Informed consent and demographic information was taken from all the patients. Patients underwent ophthalmic clinical examination that included slit lamp examination to grade pterygium. Before starting 5-FU injections, all topical medication was stopped. After four weeks the effects of 5-FU and its efficacy was noted. The patients were reviewed again after six months to note any recurrence. All the collected data was entered and analyzed on Statistical Package for Social Sciences (SPSS) version 20 (IBM Corp., Armonk, NY). Results In our study the mean age of the patients was 37.74 ± 10.15 years, male to female ratio of the patients was 1.06:1. The primary type of pterygium was noted in 54 (53.5%) and recurrent was noted in 47 (46.5%) patients. The efficacy achieved in 88 (87.13%) patients, four had recurrence of pterygium and of 101 patients 26 underwent surgical excision. Conclusion The use of 5-FU is safe and effective for the treatment of pterygium and it can be implemented as a primary treatment especially in the hot temperate zone where it is very common and aggressive with high recurrence rate. 5-FU not only halts its progression but also reduces the size and vascularity thus decreasing the need for surgery and steroid use and preventing recurrence.
Copyright © 2021, Shah et al.

Entities:  

Keywords:  5 fluorouracil; 5fu; efficacy; primary pterygium; pterygium; recurrent pterygium

Year:  2021        PMID: 33489629      PMCID: PMC7805499          DOI: 10.7759/cureus.12652

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  18 in total

1.  Fluorinated pyrimidines, a new class of tumour-inhibitory compounds.

Authors:  C HEIDELBERGER; N K CHAUDHURI; P DANNEBERG; D MOOREN; L GRIESBACH; R DUSCHINSKY; R J SCHNITZER; E PLEVEN; J SCHEINER
Journal:  Nature       Date:  1957-03-30       Impact factor: 49.962

2.  Ophthalmic pterygium: a stem cell disorder with premalignant features.

Authors:  Jeanie Chui; Minas T Coroneo; Lien T Tat; Roger Crouch; Denis Wakefield; Nick Di Girolamo
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 3.  The role of heredity in pterygium development.

Authors:  Peter Anguria; James Kitinya; Sam Ntuli; Trevor Carmichael
Journal:  Int J Ophthalmol       Date:  2014-06-18       Impact factor: 1.779

4.  Intraoperative mitomycin C to prevent recurrence of pterygium after excision: a 30-month follow-up study.

Authors:  D S Lam; A K Wong; D S Fan; S Chew; P S Kwok; M O Tso
Journal:  Ophthalmology       Date:  1998-05       Impact factor: 12.079

5.  Inefficacy of low-dose intraoperative fluorouracil in the treatment of primary pterygium.

Authors:  M J Maldonado; J Cano-Parra; A Navea-Tejerina; A L Cisneros; E Vila; J L Menezo
Journal:  Arch Ophthalmol       Date:  1995-11

Review 6.  Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.

Authors:  Ursula Amstutz; Tanja K Froehlich; Carlo R Largiadèr
Journal:  Pharmacogenomics       Date:  2011-09       Impact factor: 2.533

7.  Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.

Authors:  K E Caudle; C F Thorn; T E Klein; J J Swen; H L McLeod; R B Diasio; M Schwab
Journal:  Clin Pharmacol Ther       Date:  2013-08-29       Impact factor: 6.875

8.  In vitro modulation of interleukin-2-mediated human peripheral mononuclear cell proliferation and antitumor cytotoxicity by 5-fluorouracil.

Authors:  Eli Brazowski; Karin Eytan; Avi Eisenthal
Journal:  Anticancer Res       Date:  2007 Nov-Dec       Impact factor: 2.480

9.  [Safety and efficacy of intraoperative 5-fluorouracil infiltration in pterygium treatment].

Authors:  Vanessa Grandi Valezi; Silvana Artioli Schellini; Magda Massae Hata Viveiros; Carlos Roberto Padovani
Journal:  Arq Bras Oftalmol       Date:  2009 Mar-Apr       Impact factor: 0.872

10.  Prevalence and risk factors for pterygium in rural older adults in Shandong Province of China: a cross-sectional study.

Authors:  Wanzhen Jiao; Chengchao Zhou; Ting Wang; Shaoyuan Yang; Hongsheng Bi; Liping Liu; Yan Li; Lihua Wang
Journal:  Biomed Res Int       Date:  2014-06-12       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.